GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm

Roth Mkm initiated coverage on shares of GT Biopharma (NASDAQ:GTBP) in a report published on Monday, MarketBeat.com reports. The firm issued a buy rating and a $11.00 price objective on the stock.

GT Biopharma Stock Down 0.4 %

Shares of NASDAQ:GTBP opened at $2.79 on Monday. The company has a 50 day moving average price of $2.66 and a two-hundred day moving average price of $2.74. GT Biopharma has a 52 week low of $1.92 and a 52 week high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.